Variables | In-house mortality | |
---|---|---|
Exp (B)/HR | p value | |
Sex (male = 1) | 0.571 | .482 |
Age | 1.072 | .137 |
BMI | 1.083 | .349 |
ASA scale | 3.309 | .090 |
Primary tumor | ||
 Pancreatic adenocarcinoma | 1 |  |
 Other primary tumors | 0.612 | .521 |
Synchronous/metachronous PC | ||
 Synchronous PC | 0.438 | .299 |
 Metachronous PC | 1 |  |
Distant metastasis (no. = 1) | 0.786 | .789 |
Preoperative chemotherapy (no.=1) | 2.571 | .348 |
Sodium | 0.996 | .963 |
Hemoglobin | 0.824 | .350 |
Platelet count | 1.000 | .977 |
Total bilirubin | 0.989 | .954 |
Prothrombin time | 0.973 | .267 |
INR | 20.409 | .211 |
Albumin | 0.946 | .348 |
Creatinine | 1.047 | .967 |
CRP | 1.009 | .418 |
Laparoscopic surgery (no. = 1) | n.a. | n.a. |
Concomitant hepaticojejunostomy (no. = 1) | 0.292 | .277 |
Operative procedure | ||
 Antecolic approach | 0.000 | .999 |
 Retrocolic approach | 1 |  |
Operation time (min) | 1.000 | .975 |
Intraoperative blood transfusion (no. = 1) | 0.625 | .687 |
Intraoperative fresh frozen plasma (no. = 1) | 0.000 | .999 |